Core Viewpoint - Rosen Law Firm is reminding investors who purchased REGENXBIO, Inc. securities between February 9, 2022, and January 27, 2026, of the April 14, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased REGENXBIO securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 14, 2026 [3]. - The lawsuit alleges that REGENXBIO provided misleading information regarding its gene therapy product candidate RGX-111, which is intended for treating severe Mucopolysaccharidosis Type I [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms issuing notices may lack the necessary experience [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a record settlement against a Chinese company and significant recoveries for investors in previous years [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK,, Feb. 25, 2026 (GLOBE NEWSWIRE) -- ...

Contact Levi & Korsinsky by April 14, 2026 Deadline to Join Class Action Against REGENXBIO Inc.(RGNX) [Accessibility Statement] Skip NavigationNEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in REGENXBIO Inc. ("REGENXBIO" or the "Company") (NASDAQ: RGNX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of REGENXBIO investors who were adversely affected by alleged securities fraud between February 9, 2022 and January 27, 202 ...

REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights [Accessibility Statement] Skip NavigationROCKVILLE, Md., Feb. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 5, at 8:00 a.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2025, and operational highlights.Listeners can register for the webcast via this ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of REGENXBIO, Inc. securities during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and the efficacy of its product candidate RGX-111 [1][5]. Group 1: Class Action Details - The class action lawsuit is on behalf of investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by April 14, 2026, to represent other class members in the litigation [1][3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 and has been ranked highly for its performance in securities class action settlements [4]. Group 3: Case Specifics - The lawsuit alleges that REGENXBIO provided misleading information regarding its gene therapy product RGX-111, which is intended for treating severe Mucopolysaccharidosis Type I [5]. - Defendants reportedly made positive assertions about RGX-111's trial success while concealing adverse facts about its efficacy and safety [5].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - February ...

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against REGENXBIO Inc. (“Regenxbio” or the “Company”) (NASDAQ: RGNX).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Regenxbio and certain of it ...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2026 in REGENXBIO Lawsuit - RGNX [Accessibility Statement] Skip NavigationNEW YORK, Feb. 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX).Shareholders who purchased shares of RGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any r ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in REGENXBIO Inc. ("REGENXBIO" or the "Company") (NASDAQ: RGNX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of REGENXBIO investors who were adversely affected by alleged securities fraud between February 9, 2022 and January 27, 2026. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/regenxbio-inc-lawsuit-s ...

Group 1 - The Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of REGENXBIO, Inc. securities between February 9, 2022, and January 27, 2026 [1] - Investors who purchased REGENXBIO securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A lead plaintiff must move the Court by April 14, 2026, to represent other class members in the litigation [3] Group 2 - The lawsuit alleges that REGENXBIO provided misleading information regarding its gene therapy product candidate RGX-111, which is intended for treating severe Mucopolysaccharidosis Type I [5] - Defendants made positive assertions about RGX-111's trial success based on favorable biomarker and safety data while concealing material adverse facts about the trial's efficacy and safety [5] - The lawsuit claims that when the true details were revealed, investors suffered damages due to the misleading statements [5] Group 3 - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4] - The firm has been recognized for its success in securities class action settlements, being ranked No. 1 by ISS Securities Class Action Services in 2017 and consistently in the top 4 since 2013 [4]